Buyer beware: Therapeutic claims of probiotics marketed to crohn's disease patients via the internet lack supporting data

Inflammatory Bowel Diseases

Volumn 18, Issue 3, 2012, Pages 597-

  Adham, Kasra ^a   Dougherty, Timothy ^a   Sardana, Nitin ^a   Borum, Marie ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

COST BENEFIT ANALYSIS; CROHN DISEASE; DRUG COST; DRUG EFFICACY; DRUG MARKETING; ENTERITIS; HUMAN; INFORMATION DISSEMINATION; INTERNET; LETTER; MICROORGANISM; PRIORITY JOURNAL;

EID: 84857369373     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21637     Document Type: Letter

References (3)

1. Hedin CR, Mullard M, Sharratt E, et al. Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2010; 16: 2099-2108.
2. Chandler M, Wollins E, Toles A, et al. The emerging therapeutic role of probiotics in inflammatory bowel disease. Gastroenterol Hepatol. 2008; 4: 634-640.
3. Cima RR, Anderson KJ, Larson DW, et al. Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis. 2007; 13: 1266-1270. (Pubitemid 47597774)